Split Autoimmune Readouts Reframe the argenx Expansion Thesis

Company argenx Event Type Phase 3 futility stop (UNITY) and positive Phase 2 topline (FB102-301) Modality FcRn antagonist Fc fragment (efgartigimod SC); anti-CD122 monoclonal antibody (FB102) Asset Efgartigimod SC; FB102 Target FcRn; CD122 (IL-2/IL-15 receptor beta chain) Disease Area Sjogren disease; celiac disease Summary argenx…